September 2025
1. MUGWANY KK, Saina M, Mugo NR, MaWhinney S, et al
   Adherence thresholds for emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis against HIV acquisition in cisgender women: A randomized directly observed dosing study.
   PLoS Med. 2025;22:e1004732.
   

   >> Share

   
   
2. SIKOMBE K, Le Tourneau N, Rice B, Pry JM, et al
   Identifying care gaps along the HIV treatment failure cascade: A multistate analysis of viral load monitoring, re-suppression, and regimen switches in Zambia.
   PLoS Med. 2025;22:e1004720.
   

   >> Share

   
   February 2025
3. MEMEDOVICH A, Steele B, Orr T, Chaudhry S, et al
   Predicting patent challenges for small-molecule drugs: A cross-sectional study.
   PLoS Med. 2025;22:e1004540.
   

   >> Share

   
   January 2025
4. BHATIA A, Preiss AJ, Xiao X, Brannock MD, et al
   Effect of nirmatrelvir/ritonavir (Paxlovid) on hospitalization among adults with COVID-19: An electronic health record-based target trial emulation from N3C.
   PLoS Med. 2025;22:e1004493.
   

   >> Share

   
   November 2023
5. GALILEYA LT, Wasmann RE, Chabala C, Rabie H, et al
   Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis.
   PLoS Med. 2023;20:e1004303.
   

   >> Share

   
   
6. OLSEN A, Beall RF, Knox RP, Tu SS, et al
   Patents and regulatory exclusivities on FDA-approved insulin products: A longitudinal database study, 1986-2019.
   PLoS Med. 2023;20:e1004309.
   

   >> Share

   
   February 2023
7. MATTHEWS LT, Atukunda EC, Owembabazi M, Kalyebera KP, et al
   High PrEP uptake and objective longitudinal adherence among HIV-exposed women with personal or partner plans for pregnancy in rural Uganda: A cohort study.
   PLoS Med. 2023;20:e1004088.
   

   >> Share

   
   October 2022
8. LOWE DM, Brown LK, Chowdhury K, Davey S, et al
   Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 x 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19.
   PLoS Med. 2022;19:e1004120.
   

   >> Share

   
   September 2022
9. TAPSOBA JD, Cover J, Obong'o C, Brady M, et al
   Continued attendance in a PrEP program despite low adherence and non-protective drug levels among adolescent girls and young women in Kenya: Results from a prospective cohort study.
   PLoS Med. 2022;19:e1004097.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share